

**Supplementary Table 5.** Specific Type of Antithrombotic Therapy in Patients with AF after TAVI

	<b>SAPT or DAPT (n=55)</b>		<b>Single OAC or SAPT+OAC (n=50)</b>		<b>DAPT+OAC (n=21)</b>	
No previous PCI (n=98)	Aspirin	1 (0.8)	Warfarin	6 (4.8)	Aspirin+Clopidogrel+Warfarin	7 (5.5)
	Clopidogrel	5 (4.0)	NOAC	11 (8.7)	Aspirin+Clopidogrel+NOAC	8 (6.3)
	Aspirin+Clopidogrel	38 (30.2)	Aspirin+Warfarin	1 (0.8)		
			Aspirin+NOAC	5 (4.0)		
			Clopidogrel+Warfarin	3 (2.4)		
		Clopidogrel+NOAC	13 (10.3)			
Previous PCI (n=28)	Aspirin	1 (0.8)	NOAC	4 (3.2)	Aspirin+Clopidogrel+Warfarin	1 (0.8)
	Aspirin+Clopidogrel	10 (7.9)	Clopidogrel+NOAC	7 (5.5)	Aspirin+Clopidogrel+NOAC	5 (4.0)

AF, atrial fibrillation; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; SAPT, single antiplatelet therapy; TAVI, transcatheter aortic valve implantation.

Data are presented as n (%) of the total study population.